Clinical Trial

CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma

Study acronym: REACH-CD30
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-04.
Trial Details
NCT Number NCT07575893
Lead Sponsor New York Medical College
Collaborators: University of North Carolina, Memorial Sloan Kettering Cancer Center
Conditions Classical Hodgkin Lymphoma
Enrollment 12 participants
Start Date 2026-10-01
Primary Completion 2031-12-01 (estimated)
Study Completion 2032-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-20